Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Ophthalmic Drugs Devices Market

ID: MRFR/Pharma/51778-HCR
200 Pages
Vikita Thakur
Last Updated: March 28, 2026

UK Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Ophthalmic Drugs Devices Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Glaucoma Treatment
  50.     4.1.2 Anti-Inflammatory
  51.     4.1.3 Infection Control
  52.     4.1.4 Dry Eye Treatment
  53.     4.1.5 Retinal Disorders
  54.   4.2 Healthcare, BY Device Type (USD Billion)
  55.     4.2.1 Intraocular Lens
  56.     4.2.2 Surgical Instruments
  57.     4.2.3 Diagnostic Equipment
  58.     4.2.4 Contact Lenses
  59.     4.2.5 Ocular Drug Delivery Systems
  60.   4.3 Healthcare, BY Formulation Type (USD Billion)
  61.     4.3.1 Topical Solutions
  62.     4.3.2 Injectable Solutions
  63.     4.3.3 Ocular Implants
  64.     4.3.4 Sustained Release Formulations
  65.     4.3.5 Ophthalmic Gels
  66.   4.4 Healthcare, BY End User (USD Billion)
  67.     4.4.1 Hospitals
  68.     4.4.2 Ophthalmology Clinics
  69.     4.4.3 Ambulatory Surgical Centers
  70.     4.4.4 Home Care Settings
  71.   4.5 Healthcare, BY Distribution Channel (USD Billion)
  72.     4.5.1 Pharmacies
  73.     4.5.2 Online Retail
  74.     4.5.3 Hospital Pharmacies
  75.     4.5.4 Specialty Stores
  76. 5 SECTION V: COMPETITIVE ANALYSIS
  77.   5.1 Competitive Landscape
  78.     5.1.1 Overview
  79.     5.1.2 Competitive Analysis
  80.     5.1.3 Market share Analysis
  81.     5.1.4 Major Growth Strategy in the Healthcare
  82.     5.1.5 Competitive Benchmarking
  83.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  84.     5.1.7 Key developments and growth strategies
  85.       5.1.7.1 New Product Launch/Service Deployment
  86.       5.1.7.2 Merger & Acquisitions
  87.       5.1.7.3 Joint Ventures
  88.     5.1.8 Major Players Financial Matrix
  89.       5.1.8.1 Sales and Operating Income
  90.       5.1.8.2 Major Players R&D Expenditure. 2023
  91.   5.2 Company Profiles
  92.     5.2.1 Novartis (GB)
  93.       5.2.1.1 Financial Overview
  94.       5.2.1.2 Products Offered
  95.       5.2.1.3 Key Developments
  96.       5.2.1.4 SWOT Analysis
  97.       5.2.1.5 Key Strategies
  98.     5.2.2 Allergan (GB)
  99.       5.2.2.1 Financial Overview
  100.       5.2.2.2 Products Offered
  101.       5.2.2.3 Key Developments
  102.       5.2.2.4 SWOT Analysis
  103.       5.2.2.5 Key Strategies
  104.     5.2.3 Bausch Health (GB)
  105.       5.2.3.1 Financial Overview
  106.       5.2.3.2 Products Offered
  107.       5.2.3.3 Key Developments
  108.       5.2.3.4 SWOT Analysis
  109.       5.2.3.5 Key Strategies
  110.     5.2.4 Regeneron Pharmaceuticals (GB)
  111.       5.2.4.1 Financial Overview
  112.       5.2.4.2 Products Offered
  113.       5.2.4.3 Key Developments
  114.       5.2.4.4 SWOT Analysis
  115.       5.2.4.5 Key Strategies
  116.     5.2.5 Santen Pharmaceutical (GB)
  117.       5.2.5.1 Financial Overview
  118.       5.2.5.2 Products Offered
  119.       5.2.5.3 Key Developments
  120.       5.2.5.4 SWOT Analysis
  121.       5.2.5.5 Key Strategies
  122.     5.2.6 Hoya Corporation (GB)
  123.       5.2.6.1 Financial Overview
  124.       5.2.6.2 Products Offered
  125.       5.2.6.3 Key Developments
  126.       5.2.6.4 SWOT Analysis
  127.       5.2.6.5 Key Strategies
  128.     5.2.7 Carl Zeiss AG (GB)
  129.       5.2.7.1 Financial Overview
  130.       5.2.7.2 Products Offered
  131.       5.2.7.3 Key Developments
  132.       5.2.7.4 SWOT Analysis
  133.       5.2.7.5 Key Strategies
  134.     5.2.8 Johnson & Johnson (GB)
  135.       5.2.8.1 Financial Overview
  136.       5.2.8.2 Products Offered
  137.       5.2.8.3 Key Developments
  138.       5.2.8.4 SWOT Analysis
  139.       5.2.8.5 Key Strategies
  140.     5.2.9 Merck & Co. (GB)
  141.       5.2.9.1 Financial Overview
  142.       5.2.9.2 Products Offered
  143.       5.2.9.3 Key Developments
  144.       5.2.9.4 SWOT Analysis
  145.       5.2.9.5 Key Strategies
  146.   5.3 Appendix
  147.     5.3.1 References
  148.     5.3.2 Related Reports
  149. 6 LIST OF FIGURES
  150.   6.1 MARKET SYNOPSIS
  151.   6.2 UK MARKET ANALYSIS BY APPLICATION
  152.   6.3 UK MARKET ANALYSIS BY DEVICE TYPE
  153.   6.4 UK MARKET ANALYSIS BY FORMULATION TYPE
  154.   6.5 UK MARKET ANALYSIS BY END USER
  155.   6.6 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  156.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  157.   6.8 RESEARCH PROCESS OF MRFR
  158.   6.9 DRO ANALYSIS OF HEALTHCARE
  159.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  160.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  161.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  162.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  163.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  164.   6.15 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE)
  165.   6.16 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion)
  166.   6.17 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  167.   6.18 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  168.   6.19 HEALTHCARE, BY END USER, 2024 (% SHARE)
  169.   6.20 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  170.   6.21 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  171.   6.22 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  172.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  173. 7 LIST OF TABLES
  174.   7.1 LIST OF ASSUMPTIONS
  175.     7.1.1
  176.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  177.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  178.     7.2.2 BY DEVICE TYPE, 2026-2035 (USD Billion)
  179.     7.2.3 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  180.     7.2.4 BY END USER, 2026-2035 (USD Billion)
  181.     7.2.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
  182.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  183.     7.3.1
  184.   7.4 ACQUISITION/PARTNERSHIP
  185.     7.4.1

UK Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Glaucoma Treatment
  • Anti-Inflammatory
  • Infection Control
  • Dry Eye Treatment
  • Retinal Disorders

Healthcare By Device Type (USD Billion, 2026-2035)

  • Intraocular Lens
  • Surgical Instruments
  • Diagnostic Equipment
  • Contact Lenses
  • Ocular Drug Delivery Systems

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Topical Solutions
  • Injectable Solutions
  • Ocular Implants
  • Sustained Release Formulations
  • Ophthalmic Gels

Healthcare By End User (USD Billion, 2026-2035)

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings

Healthcare By Distribution Channel (USD Billion, 2026-2035)

  • Pharmacies
  • Online Retail
  • Hospital Pharmacies
  • Specialty Stores

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓